Personal Genome Diagnostics is adding to its IP portfolio to further develop new kinds of cancer tests.
A licensing deal announced Wednesday gives the Canton-based company exclusive rights to develop and commercialize products based on a key discovery at Memorial Sloan Kettering Cancer Center in New York. Financial terms were not disclosed.
{iframe}https://technical.ly/baltimore/2018/02/28/pgdx-signs-licensing-deal-memorial-sloan-kettering-cancer-center/?utm_campaign=Baltimore%20Editorial%20Email&utm_source=hs_email&utm_medium=email&utm_content=61077898&_hsenc=p2ANqtz-9qYm_jcgllypTf7ITpSpeEM18kaXCCsh6-xGfB20OBlmd1HDo8QEVyPR7ZZfwoZCXGnpVTR0r_bvm-2VtVEVXJHdv53w&_hsmi=61077898{/iframe}